…

The biopharmaceutical classification framework provides useful context for interpreting the permeability results reported in this study. Compounds with apparent permeability coefficients below approximately 1 × 10⁻⁶ cm/s in Caco-2 models are generally considered to have poor intestinal absorption potential, while values above this threshold suggest moderate absorption. The finding that lipid nanocapsule formulation shifted the triterpenic esters across this boundary is therefore meaningful from a drug development perspective, because pentacyclic triterpenes have historically been hampered by the combination of very poor aqueous solubility and limited membrane passage. Ursolic acid itself, despite its high measured permeability in this system, illustrates a common trap in permeability screening: a compound may cross an epithelial monolayer efficiently in vitro while simultaneously damaging the very barrier being measured. The observation that free ursolic acid disrupted epithelial integrity after two hours of incubation, with effects persisting throughout the following forty-eight hours, suggests that its high apparent permeability may partly reflect compromised tight junctions rather than purely transcellular transport. Encapsulation within lipid nanocapsules preserved barrier integrity at the same concentration while still delivering measurable transport, which is precisely the kind of trade-off that formulation scientists must balance when advancing cytotoxic natural products toward oral use.

The Caco-2 model used in this work deserves some explanation for readers unfamiliar with intestinal permeability screening. Caco-2 cells are derived from a human colorectal adenocarcinoma and, when grown as confluent monolayers on permeable supports over roughly three weeks, spontaneously differentiate into enterocyte-like cells that form tight junctions and express many of the transporters and efflux pumps found in the small intestine. Measuring the rate at which a compound crosses this monolayer yields an apparent permeability coefficient that correlates reasonably, though imperfectly, with human fractional absorption. The model has well-known limitations: it lacks the mucus layer, the villus architecture, and the full complement of metabolic enzymes present in vivo, and it tends to overestimate the impact of certain efflux transporters. Nevertheless, it remains the gold-standard in vitro screen, and the development of a validated UPLC–MS method with a limit of detection of 2 nM and a limit of quantification of 25 nM was an essential prerequisite for these experiments. Without such analytical sensitivity, the low concentrations of highly lipophilic triterpenes crossing the monolayer would have been impossible to quantify reliably, particularly given the tendency of these molecules to adsorb to plastic surfaces and partition into lipid compartments.

Lipid nanocapsules themselves occupy an interesting niche among nanocarrier platforms. Unlike polymeric nanoparticles, which release their payload largely by diffusion through a polymer matrix, or liposomes, which are bounded by a phospholipid bilayer, lipid nanocapsules feature a liquid oily core of medium-chain triglycerides surrounded by a cohesive shell of surfactants. This architecture allows very high loading of lipophilic molecules, which partition favorably into the triglyceride core, and the phase-inversion temperature manufacturing process avoids organic solvents entirely, an advantage for both scalability and regulatory acceptability. The process exploits the temperature-dependent inversion of an oil-in-water emulsion to a water-in-oil emulsion and back, trapping the drug-loaded oil phase in nanoscale droplets. Because the method requires only gentle stirring and temperature cycling rather than high-pressure homogenization, it is comparatively inexpensive and well suited to production in resource-limited settings, a non-trivial consideration for medicines intended for neglected tropical diseases prevalent in sub-Saharan Africa.

The choice of the three test compounds also reflects a rational progression in natural product drug discovery. Ursolic acid is a widely distributed pentacyclic triterpene with documented activity against a broad range of parasites, but its potency is generally modest and its developability is poor. The 8TTE mixture, comprising four feruloyl and four coumaroyl ester isomers on ursane and oleanane skeletons, represents a semi-synthetic optimization strategy in which aromatic acyl groups are appended to the C-27 position to enhance antimalarial activity; the decision to retain the isomers as a mixture rather than pursue individual purification was pragmatic, since the E and Z isomers interconvert after purification and display equivalent in vitro activity. UAOPP, the O-phenyl propionate ester at C-3, emerged from medicinal chemistry efforts to reduce the cytotoxicity of the parent triterpene while preserving antitrypanosomal activity, and its previously demonstrated selectivity index exceeding 40 on the WI-38 normal lung fibroblast line, together with significant parasitemia suppression in infected mice, marked it as the most advanced lead of the three. Testing all three within the same nanocarrier platform allowed the authors to disentangle compound-specific effects from formulation effects.

The antiparasitic assay results highlight a subtlety that is easy to overlook in nanomedicine studies: the contribution of the carrier itself. Blank lipid nanocapsules were non-toxic to Plasmodium falciparum only up to 165 μg/mL and to Trypanosoma brucei brucei only up to 65 μg/mL, concentrations at which the formulated ursolic acid and 8TTE showed enhanced antiplasmodial activity that was nonetheless comparable to that of the blank carriers. This means that for the malaria assays, at least part of the apparent improvement in activity could be attributed to the nanocapsules rather than to a genuine potentiation of the triterpenes. Such findings underscore the importance of including blank-carrier controls at matched concentrations in every antiparasitic evaluation; without them, formulation effects can be misattributed to the drug. The situation was different for UAOPP, where the loaded nanocapsules produced a roughly twenty-percentage-point improvement in antitrypanosomal activity at 2.15 μM, reducing cell viability of the parasite to about 38 percent compared with about 20 percent viability under free compound, a difference that cannot be explained by carrier toxicity alone and points to genuine enhancement of intracellular drug exposure, possibly through improved uptake of the nanocapsules by the bloodstream-form parasites or by protection of the ester from hydrolysis in the assay medium.

The distinction between the malaria and trypanosome results may also reflect biological differences between the two parasites. Plasmodium falciparum inhabits erythrocytes, so any nanocarrier must first negotiate the red cell membrane or release its payload in plasma before the drug can reach the intraerythrocytic parasite, a demanding sequence of events in a static in vitro assay. Trypanosoma brucei, by contrast, lives free in the bloodstream as an extracellular trypomastigote, directly exposed to nanoparticles in the medium, which may facilitate carrier-mediated delivery. Bloodstream-form trypanosomes are also notably endocytically active, taking up membrane and soluble proteins at high rates through their flagellar pocket, a feature that has been exploited by other nanoparticle systems and could plausibly explain why UAOPP-loaded nanocapsules outperformed the free compound against Tbb while the antiplasmodial gains were more ambiguous.

From a translational standpoint, the study’s limitations are acknowledged by the authors and merit emphasis. Caco-2 permeability and in vitro parasite assays, however well controlled, cannot capture the pharmacokinetic realities of oral administration: dissolution in gastrointestinal fluids, interaction with food and bile salts, enzymatic degradation, first-pass hepatic metabolism, and plasma protein binding all shape the ultimate exposure. Ursolic acid in particular is known to undergo extensive phase II metabolism, with glucuronidation and sulfation limiting systemic levels of the parent compound, and it remains to be seen whether nanocapsule encapsulation shields the molecule from these pathways in vivo. The ester bonds in 8TTE and UAOPP add another layer of complexity, since intestinal esterases and plasma carboxylesterases may cleave the acyl groups, potentially regenerating the parent triterpene with its own distinct pharmacology. Whether this prodrug-like behavior is beneficial or detrimental will only emerge from in vivo pharmacokinetic studies, which the authors correctly identify as the necessary next step.

The broader significance of the work lies in its demonstration that a single, solvent-free, scalable nanocarrier platform can accommodate chemically related but distinct triterpenic scaffolds and measurably improve the developability of each. Neglected tropical diseases such as human African trypanosomiasis and malaria continue to impose enormous burdens, with the World Health Organization estimating 263 million malaria cases and 597,000 deaths in 2023, concentrated among children under five in sub-Saharan Africa, while sleeping sickness, though reduced to fewer than a thousand reported cases in 2019, still leaves millions at risk across thirty-six endemic countries. Treatments for both diseases suffer from toxicity, complex dosing regimens, emerging resistance, and logistical barriers in remote settings, making oral formulations of new chemical entities particularly valuable. If subsequent in vivo studies confirm that lipid nanocapsule encapsulation translates into improved oral bioavailability and therapeutic efficacy, this approach could offer a practical route for converting lipophilic natural product leads, a historically underexploited chemical space, into viable oral medicines for populations that need them most.

Subject of Research: …

Article Title: Antiparasitic triterpenic ester and ursolic acid lipid nanocapsule design, cytotoxicity, and permeability evaluation for oral delivery

Article References: Schioppa, L., Michalowski, C. B., Mamede, L., Terrasi, R., Hérent, M.-F., Muccioli, G. G., Frédérick, R., Frederich, M., Beloqui, A., & Quetin-Leclercq, J. (2026). Antiparasitic triterpenic ester and ursolic acid lipid nanocapsule design, cytotoxicity, and permeability evaluation for oral delivery. Frontiers in Drug Delivery, 6, Article 1846904. https://doi.org/10.3389/fddev.2026.1846904

Image Credits: AI Generated

DOI: 10.3389/fddev.2026.1846904

Keywords: Antiparasitic, triterpenic, ester, ursolic, acid, lipid, nanocapsule, design, cytotoxicity, permeability, evaluation, oral